Skip to main content
Premium Trial:

Request an Annual Quote

Simon Bennett, Karen Dawes, Darlene Solomon, William Linton, Steve Trevisan

Premium

British molecule array-technology company Solexa has appointed Simon Bennett as business development director [see 4/11/03 SNPtech Reporter for company profile]. Bennett was previously director of business development at Oxagen, where he established and led genetics programs in the areas of osteoporosis, endometriosis, and women’s health. Before Oxagen, he was a research fellow at the Wellcome Trust Centre for Human Genetics.


Karen Dawes has been named to the board of directors of Genaissance Pharmaceuticals. Dawes, who is also a director at Protein Design Labs, is principal at the consulting group Knowledgeable Decisions, which focuses on biotech and emerging pharma companies, and has previously worked as senior vice president and US Business group head at Bayer. She also has worked at Wyeth Pharmaceuticals, Genetics Institute, and Pfizer.


Darlene Solomon has been named vice president and director of Agilent Laboratories, to replace Tom Saponas, who is retiring. Solomon serves on the National Science Foundation’s external advisory board for its Nanobiotechnology Center, and the policy board for the Defense Advanced Research Projects Agency Center for Biochemical Optoelectronic Microsystems.

At Agilent, Solomon was most recently director of Agilent Labs’ life science technologies laboratory, and was a senior director of research and development/technology for the company’s life sciences and chemical analysis business. She joined Hewlett-Packard Laboratories — which later spun off Agilent — in 1984, as a technical staffer. Prior to her work industry, Solomon was a researcher at Stanford University and MIT.


William Linton has joined the board of directors of High Throughput Genomics. Linton is a founder and CEO of Promega, as well as a director for Bruker Biosciences, and a member of the advisory board for the Medical College of Wisconsin’s cardiovascular center.


Steve Trevisan, executive vice president and a director of Gene Logic, will step down, but will continue “in an advisory capacity” until the end of the year. Trevisan joined Gene Logic in April as part of its acquisition of Therimmune Research [see 2/28/03 SNPtech Reporter], where he was president and CEO. Trevisan’s resignation, which Therimmune said was agreed to mutually, comes as Gene Logic moves to integrate fully Therimmune Research under the Gene Logic brand name [see related story, page 9].

Before founding Therimmune in 1998, Trevisan was president of Perot Systems Communications, which does billing systems for the telecommunications industry, the company said.

 

Filed under

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.